Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.
We studied the correlation between response to fluvoxamine and serotonin transporter gene promoter region polymorphism (5-HTTLPR). Eighteen children with autistic disorder completed a 12-week double-blind, placebo-controlled, randomized crossover study of fluvoxamine. Behavioral assessments were obtained before and at 12 weeks of treatment. 5-HTTLPR (long (l) or short(s)), was analyzed by the PCR method. Ten out of 18 patients responded to fluvoxamine treatment; allele type analysis revealed that clinical global effectiveness was noted significantly more in the l allele than in the s allele. However, with respect to language use, a significant effectiveness was noted in the s allele. 5-HTTLPR may influence the individual responses to fluvoxamine administration.
Sugie
Yoko
Y
Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan. y-sugie@umin.ac.jp
Sugie
Hideo
H
Fukuda
Tokiko
T
Ito
Masataka
M
Sasada
Yumiko
Y
Nakabayashi
Mutsumi
M
Fukashiro
Kazunobu
K
Ohzeki
Takehiko
T
D000483:Alleles; D001321:Autistic Disorder / Q000188:drug therapy* / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D004311:Double-Blind Method; D016666:Fluvoxamine / Q000627:therapeutic use*; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D016666:Fluvoxamine; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors